CG Oncology (CGON) Enterprise Value (2023 - 2026)

CG Oncology has reported Enterprise Value for 4 years, with the latest figure at -$1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 56.33% year-over-year to -$1.1 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.1 billion (down 56.33% YoY), and the FY2025 full-year result was -$742.2 million, changed 0.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.1 billion, down from -$742.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$187.7 million in Q4 2023, with the low at -$1.1 billion in Q1 2026.
• Historically, Enterprise Value has averaged -$643.8 million across 4 years, with a median of -$670.7 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 295.37% — and 2025, when it slipped 0.02%.
• CG Oncology's Enterprise Value stood at -$187.7 million in 2023, then tumbled by 295.37% to -$742.0 million in 2024, then declined by 0.02% to -$742.2 million in 2025, then slumped by 45.02% to -$1.1 billion in 2026.
• The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$742.2 million (Q4 2025), and -$680.3 million (Q3 2025), per Business Quant data.